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Abstract
Introduction:	Tau	is	a	microtubule-	associated	binding	protein	implicated	in	neurode-
generative	tauopathies,	including	frontotemporal	dementia	(FTD)	and	Alzheimer’s	dis-
ease	(AD).	These	diseases	result	in	the	intracellular	accumulation	of	hyperphosphorylated	
tau	 in	 the	 form	of	neurofibrillary	 tangles,	 the	presence	of	which	 is	 associated	with	
cognitive deficits.
Methods: We conducted a longitudinal behavioral study to provide a profile of the 
TgTau(P301L)23027	transgenic	mouse	in	multiple	cognitive	domains	across	multiple	
ages.	P301L	is	the	tau	mutation	most	frequently	observed	in	patients	with	frontotem-
poral	dementia	with	parkinsonism	linked	to	chromosome	17	(FTDP-	17)	and	this	mouse	
model	recapitulates	the	progressive	development	of	glial	and	neurofibrillary	tangles,	
and	associated	cerebral	atrophy	observed	 in	patients.	We	examined	frontal	cortex-	
dependent	executive	function	and	attention	with	the	touchscreen	5-	choice	serial	re-
action	time	test	(5-	CSRTT)	and	assessed	the	function	of	temporal	cortical	structures	
using	novel	object	recognition	(OR).
Results:	Despite	using	sensitive	tasks,	there	were	no	apparent	changes	in	executive	
function,	attention,	or	recognition	memory	in	the	transgenic	mice	from	5	to	17	months	
of age.
Conclusions: This study represents the first comprehensive longitudinal analysis of 
cognition in the TgTauP301L mouse model and suggests that this model is not ideal for 
studying early attention and recognition memory impairments associated with tauopa-
thy.	However,	spatial	and	object	recognition	memory	impairments	were	observed	dur-
ing	follow-	up	assessments	when	the	mice	were	18	and	21	months,	respectively.	These	
impairments	are	consistent	with	previous	publications,	and	with	a	dementia-	like	phe-
notype in these mice when aged.
K E Y W O R D S
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1  | INTRODUCTION
Alzheimer’s	disease	(AD)	and	frontotemporal	dementia	 (FTD)	belong	
to a class of neurodegenerative disorders referred to as tauopathies. 
Tauopathies are histologically characterized by abnormal intracel-
lular accumulation of hyperphosphorylated tau. Encoded by the 
MAPT	gene,	tau	is	a	microtubule-	associated	binding	phosphoprotein	
involved	in	the	assembly	and	stabilization	of	the	cytoskeleton,	which	
regulates neuronal processes and axonal transport. During pathogen-
esis	of	tauopathies,	brain	dysfunction	and	degeneration	are	linked	to	
the progressive accumulation of hyperphosphorylated tau aggregates 
that	form	intracellular,	filamentous	inclusions,	and	neurofibrillary	tan-
gles	(NFT;	see	Wang,	Xia,	Grundke-	Iqbal,	&	Iqbal,	2013	for	a	review).	
Patients diagnosed with tauopathies often experience impairments 
in	multiple	mnemonic	and	nonmnemonic	cognitive	domains,	such	as	
attention and executive control.
In	human	patients,	abnormal	tau	aggregates	are	observed	in	brain	
regions	exhibiting	neuronal	loss,	suggesting	that	dysregulation	of	tau	
may cause the neuronal cell death associated with the disease pathol-
ogy	 (Gomez-	Isla	 et	al.,	 1997;	 Spires-	Jones,	 Stoothoff,	 de	 Calignon,	
Jones,	 &	 Hyman,	 2009).	 Both	 NFTs	 and	 smaller	 tau	 oligomers	 are	
associated	with	neurotoxicity	and	cognitive	deficits	(see	Ren	&	Sahara,	
2013	 for	 a	 review),	 and	 abnormal	 tau	 can	 contribute	 to	 neuronal	
dysfunction	 independently	 and	 prior	 to	NFTs	 forming	 (Berger	 et	al.,	
2007;	Rocher	 et	al.,	 2010;	 Santacruz	 et	al.,	 2005;	Wittmann,	 2001).	
For	example,	a	mouse	model	expressing	a	repressible	mutant	form	of	
tau showed improved memory and less neuronal cell loss when tau 
expression	was	suppressed,	even	though	NFTs	remained	unaffected	
(Santacruz	et	al.,	2005).
The intracellular accumulation of tau aggregates also parallels 
memory	disturbances	and	AD	diagnosis	criteria	(Braak	&	Braak,	1995;	
Ohm,	Muller,	Braak,	&	Bohl,	1995).	Because	it	may	take	up	to	40	years	
from	the	first	appearance	of	NFTs	for	a	clinical	diagnosis	of	AD,	there	
is great interest in the role of tau in the earliest cellular changes that 
lead	to	functional	deficits	(Ohm	et	al.,	1995).
Patients	 with	 tauopathies,	 such	 as	 AD	 and	 FTD,	 show	 central	
executive	 functioning	 impairment,	demonstrating	 compromised	per-
formance	on	tasks	assessing	working	memory,	attention,	and	execu-
tive	control	(Nedjam,	Devouche,	&	Barba,	2004;	Stopford,	Thompson,	
Neary,	 Richardson,	 &	 Snowden,	 2012).	 The	 specific	 strains	 of	 mis-
folded tau species generated in each disorder selectively affect dis-
tinct	brain	 regions,	which	are	vulnerable	 to	different	 forms	of	 inclu-
sions	 (Clavaguera,	 Akatsu,	 et	al.,	 2013;	 Clavaguera,	 Lavenir,	 et	al.,	
2013;	Sanders	et	al.,	2014).	For	example,	FTD	patients	with	parkin-
sonism	linked	to	chromosome	17	(FTDP-	17)	show	severe	atrophy	in	
the	 frontotemporal	 lobe,	 varying	 degrees	 of	 neurodegeneration	 in	
subcortical	nuclei,	and	tau-	positive	pretangles,	neurofibrillary	tangles,	
and	glial	 fibrillary	 tangles	 (Foster	et	al.,	1997).	However,	 the	precise	
clinical	and	histological	profile	of	FTDP-	17	is	dependent	on	the	spe-
cific	MAPT	mutation	expressed	by	an	individual	patient.	A	number	of	
mutations	 in	 the	MAPT	 gene	 have	 been	 associated	with	 FTDP-	17.	
Among	 these,	 the	P301L	mutation	 in	MAPT	exon	10	 that	 results	 in	
a	Pro→	Leu	change	at	amino	acid	301	(Bird	et	al.,	1999;	Dumanchin	
et	al.,	1998;	Hutton	et	al.,	1998;	Nasreddine	et	al.,	1999;	Rizzu,	Van	
Swieten,	Joosse,	&	Hasegawa,	1999)	 is	most	 frequently	observed	 in	
patients	with	FTDP-	17	(Poorkaj	et	al.,	2001).
Transgenic animal models that exhibit tau pathology are important 
for	developing	effective	therapeutics.	Failings	in	developing	effective	
treatments result in part from our incomplete understanding of the 
causal mechanisms underlying disease progression and the difficulty in 
recapitulating	dementia	in	animal	models,	which	impedes	translation	
to	 the	clinic.	The	 transgenic	 (TgTauP301L)	mice	expressing	 the	P301L	
mutation	within	the	longest	form	of	tau	(2N,	4R)	have	previously	been	
shown	 to	 exhibit	 tau	 pathology	 development	 in	 the	 hippocampus,	
amygdala,	and	cerebral	cortex	by	3	months	of	age,	tau-	positive	pretan-
gles	by	10	months	of	age,	and	extensive	NFTs	throughout	the	fronto-
temporal	cortex	at	18–24	months	of	age	(Murakami	et	al.,	2006).	This	
progressive	neuronal	impairment	and	accumulation	of	NFT	are	asso-
ciated	with	age-	related	cognitive	deficits,	recapitulating	the	pathology	
seen	in	patients	with	FTD	and	AD	(Murakami	et	al.,	2006;	Wakasaya	
et	al.,	2011).
To	 further	examine	 the	effects	of	P301L	mutant	 tau,	 the	aim	of	
the following study was to provide a longitudinal assessment of the 
TgTauP301L mouse model across three cognitive domains.
Firstly,	 the	 TgTauP301L	 model	 was	 evaluated	 using	 the	 5-	choice	
serial	 reaction	time	test	 (5-	CSRTT)	 to	assess	executive	function	and	
attention,	 because	 of	 the	 regional	 specificity	 of	 pathology	 in	 the	
TgTauP301L	 model	 (i.e.,	 frontotemporal	 cortex	 structures),	 and	 also	
because of the possible utility of these cognitive changes in early 
detection	 (Albert,	 Moss,	 Tanzi,	 &	 Jones,	 2001;	 Baddeley,	 Baddeley,	
Bucks,	&	Wilcock,	2001;	Collette,	Van	der	Linden,	&	Salmon,	1999;	
Lawrence	&	Sahakian,	1995;	Perry,	Watson,	&	Hodges,	2000).	Frontal	
cortex-	dependent	 executive	 function	 and	 attention	were	 examined	
at	4,	7,	12,	and	16	months	of	age	using	a	touchscreen	version	of	the	
5-	CSRTT.	 Our	 laboratory	 has	 previously	 used	 this	 task	 successfully	
with	the	3xTgAD	and	TgCRND8	models	(Romberg,	Horner,	Bussey,	&	
Saksida,	2013;	Romberg,	Mattson,	Mughal,	Bussey,	&	Saksida,	2011),	
and	the	task	is	similar	to	touchscreen-	based	tasks	used	to	study	atten-
tion	and	executive	functioning	in	patients	(Sahakian,	1993;	Sahakian	
&	Coull,	1993).
Secondly,	the	TgTauP301L model was evaluated using an object rec-
ognition task. Recognition memory represents a fundamental ability to 
identify an object and judge whether it has been previously encoun-
tered. Performance on visual recognition memory tasks is highly pre-
dictive	of	conversion	to	AD	and	impairments	are	considered	by	some	
to	be	an	early	cognitive	biomarker	of	disease	(Didic	et	al.,	2013)	and	
consistent with the extensive atrophy in medial temporal lobe struc-
tures	associated	with	AD	(Juottonen	et	al.,	1998).
Object recognition memory was assessed in the same cohort of 
TgTauP301L mice using the Decoupled version of the object recogni-
tion	(OR)	task	at	5,	8,	13,	and	17	months	of	age.	The	Decoupled	vari-
ant of OR was developed by our laboratory group and has been used 
successfully	to	 identify	memory	 impairment	 in	the	TgCRND8	mouse	
model	of	AD	(Romberg	et	al.,	2012).	The	task	allows	us	to	differenti-
ate	between	forgetting	and	false	memory,	which	is	important	because	
even	 though	 patients	 diagnosed	with	AD	exhibit	 profound	memory	
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deficits,	 they	do	not	necessarily	have	accelerated	rates	of	forgetting	
(Christensen,	Kopelman,	 Stanhope,	 Lorentz,	&	Owen,	1998;	Money,	
Kirk,	&	McNaughton,	1992).
Taken	 together,	 this	 study	 represents	 the	 first	 comprehensive	
longitudinal analysis of cognition in the TgTauP301L	mouse	model.	No	
deficits	 in	executive	 function,	attention,	or	object	 recognition	mem-
ory	were	detected	between	5	and	17	months	of	age.	Because	the	tau	
pathology	is	slow	to	develop	in	this	model,	it	is	possible	that	compen-
satory	changes	masked	some	of	the	phenotypes	(such	as	attentional	
impairment)	 seen	 in	 human	 patients.	 Follow-	up	 assessments	 using	
spatial	memory	tests	at	18	and	21	months	of	age,	however,	were	con-
sistent with previous studies demonstrating impairments in the Morris 
Water Maze and radial arm maze between 9 and 13 months of age 
(Murakami	et	al.,	2006).
2  | METHODS
2.1 | Animals
All	experiments	were	performed	in	accordance	with	Canadian	Council	
on	 Animal	 Care	 guidelines	 and	 UK	 Animals	 Scientific	 Procedures	
Act	 (1986	and	the	Amendment	Regulations	2012)	and	approved	by	
the	 Animal	 Care	 Committee	 at	 the	 University	 of	 Toronto	 and	 the	
Cambridge	 University	 local	 ethics	 committee.	 Nontransgenic	 and	
tau	P301L	 transgenic	mice	were	 generated	 as	 previously	 described	
(Murakami	et	al.,	2006).	We	studied	twenty-	six	male	mice	expressing	
a	P301L	mutant	version	of	the	longest	form	of	human	tau	[denoted	
TgTau(P301L)23027,	for	brevity	TgTauP301L]	on	the	129SvEvxFVB/N	
genetic	background	and	non-	Tg	 littermates	 (Murakami	et	al.,	2006).	
At	 the	 start	 of	 behavioral	 testing,	 mice	 (12	 Tg+ and 14 Tg−)	 were	
8–10 weeks of age. Only males were used in this study. Table 1 shows 
the sample sizes during each phase of testing.
To	determine	sample	sizes	for	our	study,	power	analyses	were	run	
on	 estimated	 effect	 sizes	 from	 previously	 published	 research	 (e.g.,	
Romberg	 et	al.,	 2011).	 For	 example,	 we	 previously	 demonstrated	
impaired	performance	on	the	5-	CSRTT	in	the	3xTgAD	mouse	model	of	
Alzheimer’s	disease	(Romberg	et	al.,	2011).	In	this	study,	sample	sizes	
were n	=	8	per	genotype	and	estimated	effect	sizes	were	large,	ranging	
from	Cohen’s	f	=	1.0–2.02.	Using	G*Power	(power	0.8;	α	=	.05),	sam-
ple sizes needed to correctly detect effects of similar size would be 
n = 6–8 per group. We started with sample sizes larger than these esti-
mates	to	enable	us	to	detect	smaller	effects,	potentially	aiding	early	
detection.	Additionally,	given	our	 longitudinal	design,	we	anticipated	
higher mortality rates at advanced ages and wanted to ensure large 
enough sample sizes to detect differences between genotypes once 
aged.
Mice	were	housed	in	groups	of	2–3	on	a	12-	hr	light	cycle	(lights	
on	19:00–07:00).	All	behavioral	 testing	was	performed	during	 lights	
off.	Mice	were	provided	with	ad	libitum	access	to	water,	but	food	was	
restricted prior to the start of behavioral testing to maintain body 
weight	 at	 85%–90%	 of	 free-	feeding	 weight	 throughout	 the	 study.	
There were no differences between the weights of the Tg+ and Tg− 
groups	at	any	time	point	(p	>	.05).
2.2 | Touchscreen 5- choice serial reaction time test 
(5- CSRTT)
Touchscreen	5-	CSRTT	(Bartko	et	al.,	2011;	Romberg	et	al.,	2011)	was	
used to evaluate attention and executive function and was conducted 
as	previously	described	(Horner	et	al.,	2013;	Mar	et	al.,	2013).	Briefly,	
mice	were	trained	to	respond	to	a	white	square	stimulus	on	the	screen	
using	 a	2-	s	 stimulus	duration	 for	 a	maximum	of	40	 trials	or	60	min	
as	the	baseline	measure.	Once	acquired,	the	subjects	were	assessed	
using	a	series	of	probe	tests,	 in	which	stimulus	duration,	delay,	and	
trials per session were systematically adjusted.
Mice	were	 tested	 in	 sound-	 and	 light-	attenuating	 boxes	with	 a	
ventilation	system,	house	light,	tone	generator,	and	infrared	light	cam-
era. The testing box enclosed a touchscreen operant chamber and 
reward	 delivery	 system	 (Campden	 Instruments	 Ltd.,	 Loughborough,	
UK).	Black	plastic	masks	with	five	response	windows	were	placed	on	
the touchscreen to minimize unintended screen contact and to help 
focus	 attention.	The	 system	was	 controlled	 by	Whisker	 and	ABETII	
software	(Campden	Instruments	Ltd.).	Each	mouse	was	assigned	to	a	
particular chamber for the entire duration of the study.
After	 completing	 pretraining	 (described	 by	 Horner	 et	al.,	 2013),	
5-	CSRTT	 training	 began.	 Each	 session	 had	 40	 trials,	 and	 stimulus	
duration	was	 systematically	 reduced	 from	8	 to	4	s,	 and	 then	 to	2	s.	
Stimulus	presentation	was	followed	by	a	5-	s	limited	hold	period	when	
responses were still counted. Responses during the stimulus presenta-
tion or the limited hold period were registered as correct if in the loca-
tion of the stimulus or incorrect if in one of the other four locations. 
After	a	response,	if	there	was	still	time	remaining	in	its	presentation,	
the stimulus was immediately removed from the screen. If no response 
was	made,	an	omission	was	recorded	and	the	mouse	received	a	5-	s	
time-	out.	Once	the	reward	was	collected,	and	following	the	5-	s	inter-
trial	 interval	 (ITI),	 the	 next	 trial	 could	 be	 initiated.	 After	 initiation	
TABLE  1 Timeline of testing and experimental design
Age (months) Behavioral task Sample size
0–2
3–4 Pretraining N	=	26	(12	Tg+ and 14 Tg−)
5 5-	CSRTT N	=	25	(12	Tg+ and 13 Tg−)
6 Decoupled OR 
(1-	and	24-	hr	
delay)
N	=	24	(11	Tg+ and 13 Tg−)
7 5-	CSRTT N	=	24	(11	Tg+ and 13 Tg−)
8 Decoupled OR 
(1-	and	24-	hr	
delay)
N	=	23	(11	Tg+ and 12 Tg−)
12 5-	CSRTT N	=	23	(11	Tg+ and 12 Tg−)
13 Decoupled OR 
(1-	and	24-	hr	
delay)
N	=	23	(11	Tg+ and 12 Tg−)
16 5-	CSRTT N	=	22	(10	Tg+ and 12 Tg−)
17 Decoupled OR 
(1-	and	24-	hr	
delay)
N	=	22	(10	Tg+ and 12 Tg−)
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and	a	5-	s	fixed	delay	period,	the	next	trial	started.	If	a	response	was	
made	during	 the	5-	s	delay	between	 initiation	and	 stimulus	onset,	 it	
was	recorded	as	a	premature	response	and	the	mouse	received	a	5-	s	
time-	out.	Once	stimulus	duration	was	2	s,	and	mice	were	performing	
at	greater	than	80%	accuracy	and	less	than	20%	omissions,	for	3	of	4	
consecutive	sessions,	they	were	moved	onto	5-	CSRTT	probe	testing.
Probe	testing	sessions	were	identical	to	the	5-	CSRTT	training	ses-
sions	with	the	exception	of	stimulus	duration,	which	was	reduced	from	
2	s	(baseline	stimulus	duration)	to	1.6,	1.0,	0.8,	and	0.6	s.	Each	stimulus	
duration	was	tested	for	two	consecutive	days,	followed	by	1	to	2	con-
secutive	days	of	 the	2-	s	baseline	stimulus	duration	to	ensure	stable	
baseline performance.
At	7-	,	12-	,	and	16-	month	time	points,	the	mice	were	tested	under	
baseline conditions with stimulus duration of 2 s. Once the mice were 
performing	at	>80%	accuracy	and	<	20%	omissions,	for	2	consecutive	
sessions,	 they	were	moved	onto	5-	CSRTT	probe	 testing.	There	was	
no difference in the number of trials to criterion between genotypes 
during the baseline training.
At	 7-	,	 12-	,	 and	 16-	month	 time	 points,	 four	 additional	 probes	
were	used.	The	stimulus	duration	was	reduced	to	0.4	and	0.2	s,	and	a	
Vigilance Probe and an Impulsivity Probe	were	included.	The	Vigilance	
Probe	used	a	2-	s	stimulus	duration	over	200	trials,	for	a	maximum	of	
90	min.	Because	of	the	extended	length	of	the	session,	the	Vigilance	
Probe is a sensitive measure for sustained attention. The Impulsivity 
Probe	used	a	2-	s	stimulus	duration	and	10-	s	delay,	instead	of	the	5-	s	
baseline	delay.	Because	of	the	longer	delay,	the	Impulsivity	Probe	is	a	
sensitive	measure	 for	 assessing	 premature	 responding	 (Dalley	 et	al.,	
2007).
The number of sessions to reach the criterion performance at 
each	stage	of	pretraining	and	5-	CSRTT	training	was	recorded.	For	the	
5-CSRTT Probes, the following behavioral variables were evaluated: 
accuracy, omissions, premature responding, perseverative responding, 
reward response latency, correct response latency, incorrect response 
latency, beam breaks front, and beam breaks back. Accuracy was defined 
as percentage correct and was calculated as the number of trials in 
which	a	response	was	made	to	a	correct	location,	divided	by	the	total	
number of both correct and incorrect trials. Omissions were defined 
as	 the	 percentage	 of	 all	 trials	 (i.e.,	 correct	+	incorrect	+	omissions)	
in which the animal made no response. Premature responses were 
defined as the number of touches made during the delay period prior 
to a stimulus appearing and was used as a measure of impulsivity. 
Perseverative responding was defined as the number of screen touches 
after	a	correct	response,	prior	to	collecting	the	reward,	and	was	used	
as a measure of compulsivity. Response latency was defined as the time 
between a stimulus appearing on the screen and the animal making 
a response. Reward response latency was defined as the time taken to 
collect	the	reward	after	a	correct	response.	Beam	breaks	were	defined	
as the number of times the mouse crossed the infrared beams near 
the	screen	(i.e.,	beam breaks front)	or	magazine	(i.e.,	beam breaks back).
Data were analyzed by converting trial data to group means on 
all	of	the	performance	measures	described	above,	and	analyzed	using	
repeated	measures	ANOVA,	with	a	within-	subject	factor	of	stimulus	
duration	 and	 a	 between-	subject	 factor	 of	 genotype.	 All	 statistical	
analyses	described	in	this	manuscript	were	conducted	with	SPSS	ver-
sion	22	and	Microsoft	Excel	version	14.4.5.	Statistical	significance	was	
set at p	<	.05,	unless	running	a	Bonferonni	post	hoc	comparison.	All	
data are presented as mean ± SEM.
2.3 | Object recognition
To	evaluate	object	recognition	memory,	the	Decoupled version of the 
OR	paradigm	was	used	(McTighe,	Cowell,	Winters,	Bussey,	&	Saksida,	
2010).	This	is	a	spontaneous	task	that	does	not	require	training	and	
takes	 advantage	 of	 a	 rodent’s	 natural	 preference	 toward	 novelty.	
Time spent exploring the novel and familiar objects is analyzed and 
used	to	infer	memory	(Ennaceur	&	Delacour,	1988).	Thirty	min	prior	
to	testing,	mice	were	brought	into	a	holding	room	that	was	illuminated	
by	a	 red	 light	and	adjacent	 to	 the	 testing	 room.	All	OR	 testing	was	
carried out under dim white light conditions. Mice were individually 
transported in a cardboard carrying box between the holding room 
and the testing room.
OR	testing	took	place	in	a	Y-	maze	(previously	described	in	Romberg	
et	al.,	2012)	made	of	homogenous	opaque	white	Perspex.	Walls	were	
30-	cm	high	and	each	arm	was	16	cm	in	 length	and	8-	cm	wide.	One	
arm	was	 used	 as	 the	 start	 arm,	 and	 the	 other	 two	 arms	were	 used	
to	present	 the	 testing	 stimuli,	which	were	 randomly	 shaped	objects	
(dimensions	approximately	10	cm	×	4	cm	×	4	cm)	secured	to	the	floor	
of	the	maze	using	Blu-	tack™.	The	maze	and	objects	were	wiped	with	
a	 50%	 ethanol	 solution	 and	 dried	 between	 trials.	The	 objects	 used	
and side of the maze in which the novel object was presented were 
counterbalanced.
Mice	 received	 two	 daily	 5-	min	 sessions	 of	 habituation	 to	 the	
empty	maze	prior	to	the	first	trial	of	OR.	At	later	time	points	(i.e.,	8,	
13,	 and	17	months	of	 age),	 only	1	day	of	habituation	 for	5	min	was	
conducted prior to testing.
Testing was divided into two phases: sample phase and test phase. 
During	the	sample	phase,	the	mouse	was	placed	in	the	start	arm	of	
the	Y-	maze	and	allowed	 to	explore	 two	 identical	objects	 located	at	
the	ends	of	the	other	two	arms	for	5	min.	Mice	were	then	removed	
from	the	maze	and	placed	 in	their	home	cage	for	either	a	1-	or	24-	
hr	delay	period.	For	the	test	phase,	mice	were	placed	back	 into	the	
same	Y-	maze	apparatus	and	presented	with	one	of	two	conditions	for	
5	min:	repeat condition or novel	condition.	For	the	repeat	condition,	
the	same	two	identical	objects	(i.e.,	familiar)	seen	during	the	sample	
phase	were	presented.	For	the	novel	condition,	two	new	(i.e.,	novel)	
identical	 objects	were	 presented.	 For	 each	 delay,	mice	were	 tested	
in	both	 the	 repeat	and	novel	 conditions,	using	distinct	object	pairs,	
for a total of four trials at each time point. Trials were separated by 
at least 48 hr to prevent interference and to prevent declining moti-
vation. Objects were counterbalanced between mice to control for 
object bias.
Exploration was defined as a mouse directing its nose to an object 
at	a	distance	of	2	cm	or	less.	Sitting	on	or	chewing	at	the	base	of	the	
object was not included as exploration. Exploration was scored blind 
to	genotype	and	condition,	using	JWatcher_V1.0,	written	in	Java[TM]	
(JWatcher,	USA).	For	Decoupled	OR,	discrimination	ratios	 (D2)	were	
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calculated for both the repeat and novel	conditions	for	each	time	delay,	
and calculated as follows: 
D2	scores	<	1	on	 the	 repeat condition suggested that the mouse 
viewed the test objects as familiar and were interpreted as a subject 
remembering the sample objects. It was hypothesized that D2 scores 
would be ~1 for the novel condition.	A	D2	<	1	in	the	novel	condition	
is	 interpreted	as	a	 false	memory,	such	that	 the	mouse	saw	the	new	
object	as	familiar	(McTighe	et	al.,	2010).	Sample	data	were	compared	
using	independent	Student’s	t	tests,	to	ensure	total	exploration	during	
the	sample	phase	was	equal	between	the	genotypes	for	each	condi-
tion.	Choice	data	were	analyzed	using	a	repeated	measures	ANOVA,	
with	post	hoc	Student’s	t contrasts.
3  | RESULTS
3.1 | No differences between Tg+ and Tg− on 
5- CSRTT measures of attention and executive control 
at 5, 7, 12, and 16 months of age
There were no differences between Tg+ and Tg− for sessions to cri-
terion	during	5-	CSRTT	pretraining,	 during	baseline	5-	CSRTT	perfor-
mance	prior	to	the	start	of	probe	testing,	or	throughout	probe	test-
ing	(p >	.05;	data	not	shown).	There	was	also	no	difference	between	
Tg+ and Tg−	 baseline	 accuracy	 at	 the	 start	 of	 5-	CSRTT	probe	 trials	
(Figure	1).
Attention	and	executive	control	were	evaluated	using	5-	CSRTT	
at	5,	7,	12,	and	16	months	of	age.	For	probes	of	decreasing	stimulus	
duration	(i.e.,	1.6,	1.0,	0.8,	0.6,	0.4,	0.2	s),	measures	of	performance	
used to compare Tg+ and Tg−	were	as	follows:	accuracy,	omissions,	
premature	 responding,	perseverative	 responding,	 reward	 response	
latency,	correct	response	latency,	incorrect	response	latency,	beam	
breaks	 front,	and	beam	breaks	back.	Repeated	measures	ANOVAs	
showed no statistically significant interactions between genotype 
and	stimulus	duration	on	any	of	the	performance	measures,	at	any	
of	 the	 time	points.	 Figure	2	 provides	 line	 graphs	 illustrating	accu-
racy,	omissions, premature responses,	 and	perseverative responses at 
5,	7,	12,	and	16	months	of	age.	Each	probe	was	run	for	two	consec-
utive	days,	so	each	data	point	is	an	average	of	the	two	days	(data	for	
other	measures	not	shown).
Similarly,	 there	were	no	statistically	 significant	effects	on	any	of	
these performance measures for the Impulsivity Probe	 (10	 s	 delay;	
Figure	3)	or	Vigilance Probe	 (200	trials;	Figure	4)	tested	at	7,	12,	and	
16	months	of	age	(p	>	.05).
3.2 | No differences between Tg+ and Tg− on 
decoupled OR with 1- or 24- hr delays at 6, 8, 13, or 
17 months of age
Mice	were	tested	on	Decoupled	OR	with	a	1-	and	24-	hr	delay	at	6,	8,	
13,	and	17	months	of	age.	There	were	no	statistically	significant	dif-
ferences in sample exploration between Tg+ and Tg− at any time point 
(data	not	shown).	Repeated	measures	ANOVAs	revealed	no	statisti-
cally	significant	 interactions	 (p >	.05)	between	D2	scores	of	Tg+ and 
Tg− on Repeat or Novel	conditions	at	6,	8,	13,	and	17	months	of	age	
(Figure	5).
4  | DISCUSSION
This study provides the first longitudinal cognitive profile of the 
TgTauP301L	mouse,	from	5	to	17	months	of	age,	using	behavioral	tasks	
to	evaluate	 attention,	 executive	 functioning,	 and	object	 recognition	
memory.	Frontal	cortex-	dependent	executive	function	and	attention	
were	evaluated	using	the	touchscreen	version	of	the	5-	CSRTT	at	4,	7,	
12,	and	16	months	of	age.	Object	recognition	memory	was	assessed	
at	 5,	 8,	 13,	 and	 17	months	 of	 age.	 Because	 the	 TgTauP301L mouse 
model	develops	tau	pathology	slowly,	there	may	have	been	sufficient	
time	for	compensatory	changes	to	mask	some	of	the	phenotypes	(e.g.,	
attentional	impairments)	typically	seen	in	patients	with	dementia.	We	
conclude that this model is not ideal for studying early impairments 
in	attention,	executive	functioning,	or	recognition	memory.	However,	
spatial and object recognition memory impairments were observed 
during	follow-	up	assessments	when	the	mice	were	18	and	21	months,	
respectively	 (see	 Appendix	 for	 the	 Supplementary	 methods	 and	
results).	These	impairments	are	consistent	with	previous	publications,	
and	with	a	dementia-	like	phenotype	in	these	mice	when	aged.
P301L	is	the	tau	mutation	most	frequently	observed	in	patients	
with	 FTDP-	17	 (Poorkaj	 et	al.,	 2001).	 The	 TgTauP301L transgenic 
mouse model has been previously shown to recapitulate the pro-
gressive	development	of	glial	fibrillary	(GFT)	and	NFT,	cerebral	atro-
phy,	 and	 age-	related	 cognitive	 impairments	 observed	 in	 patients	
(Murakami	et	al.,	2006;	Sasaki	et	al.,	2008;	Wakasaya	et	al.,	2011).	
For	 example,	 Sasaki	 et	al.	 (2008)	 compared	 immunocytochemical	
D2=
Test Phase exploration(s)
Sample Phase exploration(s)
F IGURE  1 Baseline	accuracy	at	the	start	of	5-	CSRTT	probe	
trials. The y-	axis	represents	the	mean	accuracy	(%)	for	the	final	two	
baseline sessions prior to the start of probes. There was no difference 
between Tg+ and Tg−. Data are expressed as the mean ± SEM
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analyses	of	brains	from	six	patients	with	tauopathies	(including	AD)	
and TgTauP301L mice at 11–27 months of age. The TgTauP301L mice 
showed microglial activation in gray matter associated with phos-
phorylated	 tau	 deposition,	which	was	 similar	 to	 samples	 from	 the	
human patients. There are also many similar factors responsible for 
NFT	formation	and	neuronal	cell	 loss	between	the	TgTauP301L mice 
and	both	patients	with	AD	and	FTD,	 as	demonstrated	by	compar-
ing	oligonucleotide	array	expression	(Wakasaya	et	al.,	2011).	These	
comparative studies validated the TgTauP301L mice as a model of 
tauopathies,	including	both	FTD	and	AD.
The TgTauP301L model was first characterized by Murakami et al. 
(2006),	who	reported	 initial	tau	pathology	development	 in	the	hippo-
campus,	 amygdala,	 and	cerebral	 cortex	at	approximately	3	months	of	
age	and	tau-	positive	pretangles	at	10	months	of	age.	Although	not	spec-
ified explicitly in the histological report for this cohort at 3 or 10 months 
of	age,	we	assumed	that	“cerebral	cortex”	was	referring	to	the	fronto-
temporal cortex because that was the site of the most extensive patho-
logical	markers	at	later	ages.	For	example,	extensive	NFTs	were	identi-
fied throughout the frontotemporal cortex at 18 to 24 months of age. 
Histological	 analysis	of	 another	 cohort	of	TgTauP301L at 13 months of 
F IGURE  2 5-	CSRTT	performance	on	probe	trials	using	decreased	stimulus	duration.	Line	graphs	showing	accuracy	(%),	omissions	(%),	
number of premature responses,	and	number	of	perseverative responses for Tg+ and Tg−	on	5-	CSRTT	at	5,	7,	12,	and	16	months	of	age.	The	y-	axis	
represents	the	mean	performance	value,	and	the	x-	axis	represents	the	stimulus	duration	for	each	probe.	There	were	no	statistically	significant	
interactions	between	genotype	and	stimulus	duration	for	any	performance	measure,	at	any	time	point	(p	>	.05).	Data	are	expressed	as	the	
mean ± SEM
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age	showed	that	37%	had	pretangles,	42%	had	pretangles	and	GFTs,	
and	 21%	 had	 pretangles,	 GFTs,	 and	 NFTs.	 NFTs	 were	 found	 in	 the	
cerebral	cortex,	hippocampus,	amygdala,	basal	forebrain	nucleus,	locus	
ceruleus,	 and	 substantia	 nigra.	 Glial	 tau	 pathology	 developed	 inde-
pendently and preceded neuronal cytopathology. Mice showed brain 
atrophy	by	18	months	of	age,	in	the	temporal	cortex,	including	hippo-
campus.	Tau-	positive	glial	tangles	were	also	observed	in	the	spinal	cord.	
These histological reports of the TgTauP301L model illuminate the high 
within-	cohort	variance	in	pathology.	The	authors	suggest	that	this	vari-
ance	may	be	caused	by	genetic	modifiers,	environmental	parameters,	
or	stress	(Murakami	et	al.,	2006).	The	high	variability	in	pathology	may	
explain the variability in behavior demonstrated by our cohort.
Because	 of	 the	 regional	 specificity	 of	 tau	 pathology	 in	 the	
TgTauP301L	model,	the	present	study	prioritized	tasks	dependent	upon	
the	 frontotemporal	 cortex.	The	 cohort	was	 first	 tested	on	5-	CSRTT	
because evidence suggests that executive and attentional deficits may 
be	the	earliest	cognitive	deficits	in	AD,	prior	to	deficits	in	spatial	mem-
ory	and	 language	 impairments	 (Baddeley	et	al.,	2001;	Collette	et	al.,	
1999;	 Lawrence	&	 Sahakian,	 1995;	 Perry	 et	al.,	 2000),	 and	may	 be	
a	predictive	preclinical	 feature	of	AD	(Albert	et	al.,	2001).	Given	the	
importance of early detection and the slow progression of pathology 
in	 this	model,	we	 thought	 that	 examining	 executive	 and	 attentional	
deficits provided the best chance at detecting the earliest cognitive 
changes.
To	 our	 knowledge,	 only	 limited	 behavioral	 characterization	 of	
these	mice	has	been	performed,	which	did	not	 investigate	the	earli-
est	cognitive	changes.	Murakami	et	al.	(2006)	evaluated	the	TgTauP301L 
mouse	model	on	the	Morris	Water	Maze	(MWM)	at	9	and	12	months	
of	age	and	the	eight-	arm	radial	maze	at	9	and	13	months	of	age.	Older	
cohorts	were	tested	on	the	open-	field	test,	MWM	(reference	memory	
and	visible	 cued	platform	 test),	 and	conditioned	 taste	 aversion.	The	
results showed impaired working memory at 12 and 13 months of 
age and impaired conditioned taste aversion at 16–18 months of age. 
Importantly,	unlike	the	present	study,	these	data	were	collected	from	
a	cross-	sectional	rather	than	longitudinal	design.
The present longitudinal study evaluated several cognitive 
domains.	 Firstly,	 using	 a	 touchscreen	 version	 of	 the	 5-	CSRTT,	 we	
examined	frontal	cortex-	dependent	executive	function	and	attention	
at	4,	7,	12,	and	16	months	of	age	in	the	TgTauP301L	mice.	By	comparing	
these data to the results of studies of other rodent models of demen-
tia	using	the	same	testing	method,	an	interesting	profile	of	behavioral	
differences	emerges,	which	may	be	related	to	the	precise	pathological	
insult	experienced.	Specifically,	Romberg	et	al.	(2011)	tested	attention	
and	 executive	 control	 in	 3xTgAD	mice,	which	 express	 the	APPswe,	
and	 PS1	 M146V	 mutations	 in	 concert	 with	 the	 tau	 P301L	 muta-
tion.	Subsequently,	the	TgCRND8	mouse,	a	widely	used	model	of	Aβ 
pathology,	expressing	the	Appswe/ind	mutation	was	also	evaluated	in	
this	paradigm	(Romberg	et	al.,	2013).	The	3xTgAD	model	was	found	to	
F IGURE  3 5-	CSRTT	Impulsivity	Probe.	
Accuracy	(%), omissions	(%), mean number 
of premature responses, and mean number 
of perseverative responses for Tg+ and 
Tg−	during	the	5-	CSRTT	Impulsivity	Probe	
with	a	10-	s	delay.	Bar	graphs	show	the	
performance measures at 3 time points: 
7,	12,	and	16	months	of	age.	There	were	
no statistically significant differences 
in accuracy between Tg+ and Tg− at any 
of the time points. Omission rate at 
16 months of age is higher for Tg+ than 
Tg−	but	not	statistically	different	(p =	.052).	
Premature	responses	decrease	with	age,	
which	may	be	a	result	of	learning	(main	
effect of age p	=	.04).	No	statistically	
significant differences in perseverative 
responding between Tg+ and Tg− were 
detected.	At	12	months	of	age,	Tg-	make	
more perseverative responses but it is not 
statistically	significant	(p =	.09).	Data	are	
expressed as the mean ± SEM
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perform with less accuracy and make more perseverative responses 
than	the	control	mice	at	9	months	of	age	in	this	task.	In	contrast,	4-	
to	5-	month-	old	TgCRND8	mice	exhibited	lower	accuracy,	but	no	dif-
ferences in other measures including perseverative responding. Our 
results	now	add	 to	 this	profile,	 reporting	 that	expression	of	 the	 tau	
P301L	mutation	alone	has	no	effect	on	touchscreen	5-	CSRTT	perfor-
mance across a wide range of ages.
Secondly,	 we	 examined	 the	 TgTauP301L mouse model using the 
Decoupled	OR	task.	Task	performance	was	unaffected	at	5,	8,	13,	and	
17. This suggests a remarkable functional resilience of medial temporal 
cortical	structures,	given	the	likely	extensive	nature	of	the	pathological	
insult	experienced	by	the	17-	month	time	point.	As	with	the	5-	CSRTT	
assessment,	 we	 have	 previously	 examined	 the	 performance	 of	 the	
TgCRND8	 amyloid	model	 in	 the	Decoupled	OR	paradigm.	Romberg	
et	al.	 (2012)	 found	 that	 the	 Tg+ did not perform differently on the 
repeat	and	novel	conditions	 in	the	Decoupled	OR	task,	whereas	the	
littermate controls showed higher D2 scores in the novel condition. 
This	was	 interpreted	 as	 the	 TgCRND8	 exhibiting	 recognition	mem-
ory	impairment	due	to	false	recognition	rather	than	forgetting.	False	
recognition has been reported as a cause of memory impairments 
in	 patients	with	AD	 and	 those	with	MCI	 (Abe	 et	al.,	 2011;	Budson,	
Desikan,	 Daffner,	 &	 Schacter,	 2001;	 Gold,	 Marchant,	 Koutstaal,	
Schacter,	&	Budson,	2007;	Hart,	Smith,	&	Swash,	1985;	Hildebrandt,	
Haldenwanger,	 &	 Eling,	 2009;	 Plancher,	 Guyard,	 Nicolas,	 &	 Piolino,	
2009;	Yeung,	Ryan,	Cowell,	&	Barense,	2013).	Unlike	 the	TgCRND8	
model,	no	memory	impairment	was	observed	in	the	TgTauP301L model.
Following	the	completion	of	the	longitudinal	study	and	the	strik-
ingly similar performance of the Tg+ and Tg−	groups,	we	decided	to	con-
duct further cognitive tasks and histological analysis. The methods and 
results	can	be	found	in	the	Appendix	(Table	S1).	We	assessed	spatial	
memory	using	the	hippocampus-	dependent	location	recognition	(LR)	
and	T-	maze	tasks	between	18	and	20	months	of	age,	and	recognition	
memory	using	the	Forced-	choice	version	of	OR	at	19	and	21	months	
of	 age.	 Spatial	memory	was	 assessed	 because	 previous	 studies	 had	
demonstrated impairments in this mouse model on the MWM and 
radial	 arm	maze	between	9	and	13	months	of	 age	 (Murakami	et	al.,	
2006).	The	Forced-	choice	paradigm	was	 chosen	because	 it	 requires	
half	as	many	trials	as	the	Decoupled	paradigm,	which	makes	it	faster	to	
assess	different	delays.	At	17	months	of	age,	performance	at	the	24-	hr	
delay on the repeat condition of the Decoupled version was approach-
ing	a	discrimination	ratio	of	1,	which	suggested	that	both	groups	were	
having	trouble	remembering	at	such	a	long	delay.	The	Forced-	choice	
paradigm	enabled	us	to	evaluate	intermediate	delays	(i.e.,	3	and	8	hr).	
As	the	mice	were	becoming	aged,	and	the	attrition	rate	was	increasing,	
it	was	important	to	test	different	delays	as	quickly	as	possible.
On	the	LR	 task,	 the	 results	were	variable	but	suggestive	of	mild	
spatial memory impairment in the TgTauP301L mice at 18 months of 
age	(Figure	S1).	This	observation	is	consistent	with	the	hippocampal	
F IGURE  4 5-	CSRTT	Vigilance	probe.	
Accuracy	(%), omissions	(%), mean number 
of premature responses, and mean number 
of perseverative responses for Tg+ and 
Tg−	during	the	5-	CSRTT	Vigilance probe 
with 200 trials. There were no statistically 
significant differences on any of the 
measures,	at	any	of	the	time	points.	
At	12	months	of	age,	Tg+ show more 
premature responses than Tg−	(p =	.09)	and	
Tg-	show	more	perseverative	responses	
than Tg+	(p =	.07).	Data	are	expressed	as	
the mean ± SEM
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atrophy observed in mice of the same age. Due to high levels of sub-
criterion	performance,	 it	was	not	possible	 to	draw	conclusions	 from	
the	data	collected	using	the	T-	maze	task	(Figure	S2).	Considering	the	
LR	deficit	observed	here	and	the	fact	that	spatial	deficits	have	been	
reported	in	these	mice	at	younger	ages	(Murakami	et	al.,	2006),	future	
studies	of	this	model	should	prioritize	early	detection	of	hippocampus-	
dependent	 deficits.	 For	 example,	 there	 is	 some	 evidence	 that	mice	
expressing	the	P301L	transgene	are	particularly	impaired	in	trace	fear	
conditioning	 relative	 to	other	hippocampal-	dependent	 tasks	such	as	
the	MWM	(Hunsberger	et	al.,	2014);	thus,	researchers	using	TgTauP301 
mice might consider employing trace fear conditioning tasks to detect 
the earliest memory deficits.
On	 the	 Forced-	choice	OR	 paradigm,	 the	TgTauP301L mice exhib-
ited	a	deficit	at	21	months,	but	not	at	19	months	of	age	(Figure	S3).	
However,	due	to	the	limitations	of	the	Forced-	choice	technique,	it	is	
not possible to determine whether the deficit in the TgTauP301L animals 
is	 due	 to	 false	memory	or	 forgetting.	 Future	 studies	 could	 evaluate	
TgTauP301L at 21 months of age on the Decoupled version of OR to 
confirm the nature of this deficit and enable comparison with the pre-
vious	TgCRND8	study	(Romberg	et	al.,	2013).	The	decision	to	termi-
nate the behavioral testing at 21 months of age was because of the 
uneven	 sample	 sizes,	 the	 increasing	 attrition	 rate	 of	 the	 TgTauP301L 
sample,	and	the	need	to	conduct	histological	analysis	to	confirm	tau	
pathology in the Tg+ group and the absence in Tg−	group	(Figures	S4	
and	S5).	Future	studies	should	use	larger	sample	sizes	to	investigate	
the specific impairments at such late time points.
The greatest strength of the longitudinal design is that we 
were able to control for cohort effects while identifying changes as 
pathology develops. Cohort effects are particularly relevant to trans-
genic	models,	which	 can	 be	 affected	 by	 genetic	 drift	 in	 the	 colony.	
F IGURE  5 Decoupled	OR	at	6,	8,	13,	
and	17	months	of	age.	Bar	graphs	showing	
D2 on the y-	axis,	comparing	Tg+ and Tg− on 
Repeat and Novel conditions. There were no 
statistically significant differences between 
Tg+ and Tg− at any time point. Data are 
expressed as the mean ± SEM
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Differences between cohorts caused by factors other than genotype 
and pathology are not easily ruled out when comparing cohorts of 
different ages. The repeated testing also allows for the timing of the 
onset of cognitive impairments to be detected.
A	potential	issue	with	our	longitudinal	study	would	be	the	possibil-
ity of contamination by repeated exposure to the tasks. This is partic-
ularly	a	concern	for	repeated	testing	on	the	5-	CSRTT	because	training	
and	learning	are	required.	It	is	possible	that	learning	from	the	repeated	
testing could have masked differences between the genotypes. 
However,	this	is	unlikely	because	the	mice	displayed	similar	duration-	
dependent	 performance	 at	 various	 ages,	 such	 that,	 as	 the	 duration	
of	the	stimuli	was	shortened,	performance	declined.	Additionally,	we	
were comparing between genotypes and both groups received the 
same amount of training. Contamination caused by repeated test-
ing	is	not	likely	an	issue	for	the	spontaneous	tasks	(e.g.,	OR)	because	
no	training	or	learning	is	required.	There	is	no	reason	to	expect	that	
repeated exposure to the testing chamber would affect novelty pref-
erence	during	OR,	particularly	because	all	mice	were	habituated	to	the	
chamber prior to the initial tests.
In	 summary,	 this	 study	 represents	 the	 first	 longitudinal	 behav-
ioral evaluation of the TgTauP301L mouse model of tauopathy. There 
were no apparent changes in executive function or attention in these 
animals	as	measured	in	the	touchscreen	5-	CSRTT.	However,	spatial	
and object recognition memory impairments were observed during 
follow-	up	assessments	using	LR	and	Forced-	choice	OR	tasks	when	
the	mice	were	18	and	21	months,	 respectively.	These	 impairments	
are	consistent	with	a	dementia-	like	phenotype	 in	 these	mice	when	
aged.	Thus,	despite	using	 tasks	proven	 to	be	sensitive	with	mouse	
models	of	neurodegenerative	disease	(Romberg	et	al.,	2011,	2013),	
no behavioral impairments were identified until the mice were aged. 
It seems unlikely that this was due to an absence of pathology prior 
to	18–21	months	of	age,	as	Murakami	et	al.	(2006)	showed	pretan-
gles,	GFTs,	and	NFTs	by	13	months	of	age,	and	we	observed	signifi-
cant	pathology	at	our	final	time	point.	To	conclude,	this	model	may	be	
useful for studying impairments in some aspects of cognitive func-
tion	relevant	to	neurodegenerative	disease,	at	later	stages	of	disease.	
The model may not be as useful for research aiming to detect early 
changes	in	attention,	executive	function,	and	recognition	memory.
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